Acrivon Therapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | 68.2% | 68.2% | -15.2% |
| FY2022 | -18.3% | -18.3% | -17.2% |
| FY2023 | -49.8% | -49.8% | -43.7% |
| FY2024 | -45.6% | -45.6% | -41.0% |
| FY2025 | -69.2% | -69.2% | -60.1% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | 68.2% | 68.2% | -15.2% |
| FY2022 | -18.3% | -18.3% | -17.2% |
| FY2023 | -49.8% | -49.8% | -43.7% |
| FY2024 | -45.6% | -45.6% | -41.0% |
| FY2025 | -69.2% | -69.2% | -60.1% |